April 2014 | Contemporary Oncology®

June 11, 2014

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

May 29, 2014

The recent approval of several new agents for the treatment of prostate cancer has heralded a new era for managing this condition.

May 16, 2014

More recently, researchers seek to understand the mechanisms related to tumor dissemination in hopes of therapeutically targeting this process.

April 25, 2014

The treatment decisions for NSCLC are primarily dependent on the patient's performance status, extent of disease, and histological subtype. Significant developments in the area of targeted therapies have changed the treatment paradigm for NSCLC.